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National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
Epidermal growth factor reproduces many of the effects of estrogen on the murine female reproductive tract and may partially mediate
estrogen-induced growth and differentiation. The mechanism by which the actions of estrogens and epidermal growth factor (EGF) converge is
unknown. The studies described herein were performed to investigate the possibility that some of the actions of EGF may be mediated through the
estrogen receptor. A specific estrogen receptor (ER) antagonist inhibited estrogenlike effects of EGF in the mouse uterus, specifically induction of
DNA synthesis and phosphatidylinositol turnover. In addition, EGF elicited enhanced nuclear localization of uterine ER and formation of a unique
nuclear form of ER that is present after estrogen treatment. These in vivo observations indicated that EGF may elicit some of its actions by activa-
tion of nuclear ER. Thus, the effect of peptide growth factors on activation of a consensus estrogen response element was assessed in Ishikawa
human endometrial adenocarcinoma cells, which contain negligible ER levels, and in BG-1 human ovarian adenocarcinoma cells, which contain
abundant ER. EGF and TGFa induced transcriptional activation of a consensus estrogen response element (ERE) in an ER-dependent manner in
both cell types. In addition, insulinlike growth factor (IGF-1) was as potent as 17,B-estradiol in BG-1 cells. Synergism between growth factors and
estrogen was observed in both cell types, although synergism was not observed between the different classes of growth factors [i.e., transforming
growth factor a (TGFa) and IGF-Il in BG-1 cells. The most potent activator of ERE-dependent transcription was a protein kinase C activator (TPA),
which acted synergistically with 17festradiol. A protein kinase C inhibitor abolished the effect ofTPA but not that of 17festradiol, IGF-I, orTGFa. A
protein kinase A activator elicited ER-dependent activation of transcription and did not synergize with estrogen or growth factors. In conclusion,
some physiologic actions of peptide growth factors are dependent on ER. Indeed, growth factors are capable of eliciting ER-dependent activation of
an ERE. Both the protein kinase A and protein kinase C pathways can elicit ER-dependent transcriptional activation; however, it is unlikely that these
pathways mediate the effects of peptide growth factors on the ER in BG-1 cells. - Environ Health Perspect 103(Suppl 7):35-38 (1995)
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Introduction
It has been proposed that polypeptide
growth factors may act as autocrine or
paracrine mediators ofbiological actions of
estrogen (1,2). The observations that estro-
gen induces mRNA and protein for pep-
tide growth factors [epidermal growth
factor (EGF), transforming growth factor
a (TGFa), and insulinlike growth factor I
(IGF-I)] (3-7) and their receptors (8-11)
in rodent uterus are consistent with this
hypothesis and implicate a role for the
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EGF receptor-signaling pathway in steroid
hormone regulation of uterine biology.
Our laboratory has previously demon-
strated a convergence between the actions
ofEGF and estradiol in the mouse uterus.
EGF reproduced the stimulatory effects of
estrogen on uterine DNA synthesis, lacto-
ferrin gene expression, and phosphatidyli-
nositol lipid metabolism in ovariectomized
mice (12,13). Futhermore, administration
of EGF-neutralizing antibodies before
estradiol blocks estrogen-induced uterine
epithelial cell proliferation, which suggests
that the presence ofEGF may be necessary
for estrogen-induced responses (12).
Presently, the mechanisms by which
the actions ofestrogens and growth factors
converge are unknown. These studies
address the intriguing possibility that some
biological effects ofpeptide growth factors,
which are extracellular ligands, may be
mediated through a nuclear steroid hor-
mone receptor, namely, the estrogen recep-
tor. Several reports in the literature support
this hypothesis. First, two reports by Power
et al. (14,15) demonstrated the existence
of cross talk between a membrane-associ-
ated extracellular receptor system and
nudear steroid receptors. In these studies,
dopamine elicited steroid receptor-depen-
dent activation ofsteroid response element-
regulated transcription in transfected CV1
cells. In addition, the ability of antiestro-
gens to suppress induction ofprogesterone
receptor levels and DNA synthesis by pep-
tide growth factors in MCF-7 cells (16-18)
suggests a role for the estrogen receptor in
the actions ofextracellular mitogens.
Interaction of EGFwith
Uterine Estrogen Receptors
in Vivo
The first set of experiments involved in
vivo administration of EGF via slow-
release, cholesterol-based pellets containing
1.25 psg mouse EGF per quarter pellet
implanted under the kidney capsule of
adult ovariectomized mice anesthetized
with methoxyflurane (13). The characteri-
zation of this procedure is detailed in
Nelson et al. (12). Both the pellets and the
serum ofthe mice were devoid ofestrogen,
and the mitogenic effect induced by EGF
administration in the uterus was not
affected by adrenalectomy or hypophysec-
tomy. These pellets can also be placed in
the peritoneal cavitywithout attenuation of
effect (unpublished observations). Placebo
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pellets were implanted in control animals.
Mice receiving ip injections ofdiethylstilbe-
strol (DES) or saline were sham operated.
Administration ofEGF (1.25 pg) or DES (5
pg/kg) resulted in similar inductions ofboth
DNA synthesis (10-fold at 16 hr posttreat-
ment) and phophatidylinositol turnover (2-
fold) versus respective controls. DNA
synthesis and phosphatidylinositol metabo-
lism were assessed as described (13,19). The
effects ofboth EGF and DES were inhibited
by pretreatment with 1 mg/kg of the pure
antiestrogen ICI 164,384 (provided byAlan
Wakeling, ICI Pharmaceuticals, Mereside,
United Kingdom) (20).
The ability of an ER antagonist to
block the cellular actions of EGF in the
whole animal prompted an investigation of
the effects of EGF on biochemical charac-
teristics ofthe estrogen receptor (ER) (13).
Estrogen treatment rapidly enhances ER
affinity for chromatin so that the ER is
retained in the nuclear fraction after tissue
homogenization. This phenomenon is
quantitated by a 3H-estradiol-binding assay
(21,22). Significant augmentation of
nuclear ER levels was observed 1.5 hr after
EGF pellet implantation or DES treat-
ment. Enhanced nuclear retention of ER
after EGF treatment was corroborated by
immunodetection with H222 ER mono-
clonal antibody (a gift from Chris Nolan,
Abbott Laboratories, Abbott Park, IL),
which demonstrated that there was a larger
quantity of protein in the ER-specific
bands in the uterine nuclear fractions after
EGF or DES treatment. The interaction of
the ER with the estrogen response element
(ERE) is a prerequisite for transcriptional
activation. This property of ER found in
uterine nuclear extracts from EGF-treated
mice was compared to that found after
DES treatment using a gel retardation assay
(23). In this assay, nuclear proteins were
salt extracted from uterine homogenates
and concentrated by ammonium sulfate
precipitation. The nuclear extracts were
incubated in the presence or absence of
H222 ER antibody overnight followed by
incubation with a 32P-labeled vitellogenin
A2 consensus ERE. The resulting com-
plexes were separated on a 5.625% poly-
acrylamide gel. The band-shifting pattern
observed after EGF treatment was very
similar to that seen after DES administra-
tion. The two specific ER- ERE complexes
present after EGF or DES treatment were
supershifted by H222 antibody, which
demonstrated that immunoreactive ER was
present in these complexes. These results
suggest that the nuclear ER from EGF-
treated mice interacts with an ERE in a
manner similar to that observed after estro-
gen treatment. It has previously been
demonstrated that estrogen treatment
induces heterogenous nuclear ER forms of
65- and66.5-kDa in uterine nudear extracts
(22) and that the 66.5-kDa form is hyper-
phosphorylated ER (24). Similar to the
effect of estrogen, EGF treatment elicited
the formation of the unique nuclear 66.5-
kDa form ofER as assessed by immunode-
tection with H222 antibody. This form was
not observed in the uterine cytosolic frac-
tions from EGF- or DES-treated mice.
In summary, some estrogenlike effects
ofEGF in the uterus are dependent on the
estrogen receptor. Furthermore, EGF elic-
its biochemical modifications ofthe uterine
estrogen receptor that are similar to those
of estrogen. Thus, cross talk may indeed
exist between EGF and ER-signaling sys-
tems. This evidence suggests a role for the
ER in mediating physiological actions of
EGF in the reproductive tract in the
absence ofestradiol.
Peptide Growth Factor
Regulation of Estrogen
Receptor-dependent
Activation of an Estrogen
Response Element
The following studies were performed to
assess whether peptide growth factors could
activate transcription from a consensus
estrogen response element in an ER-depen-
dent manner. To accomplish this goal, we
first used Ishikawa human endometrial ade-
nocarcinoma cells, which contain negligible
levels of ER, in transfection experiments
(25). Ishikawa cells were plated on 6-well
plates and grown in DMEM/F-12 media
containing 5% fetal bovine serum. At 50%
confluency, the cells were transfected with 2
jg ofpCAT sv40 promoter reporter vector
(Promega, Madison, WI) containing a con-
sensus vitellogenin A2 ERE sequence
(2 pg/well) and 0.15 pg ofpSG5 expression
vector (Stratagene Cloning Systems, Inc.,
Lajolla, CA) containing the full-length
cDNA for mouse ER (gift from Malcolm
Parker) using transfectam (Promega). The
cells were maintained in serum-free
medium from the time oftransfection until
harvest. Cells were treated with 100 ng/ml
of human recombinant EGF or TGFa or
with 170-estradiol for 18 hr before harvest.
Cells were frozen and thawed to obtain
supernatants in which chloramphenicol
acetyltransferase (CAT) enzyme activitywas
assayed, as previouslydescribed (25).
Neither 17,-estradiol nor the peptide
growth factors elicited a change in expres-
sion of the reporter gene (CAT) in the
absence of ER transfection or in the pres-
ence ofthe control reporter vector (without
ERE). However, in Ishikawa cells trans-
fected with both vitA2 ERE pCAT and the
ER expression vector, both EGF and TGFa
as well as 17p-estradiol elicited transcrip-
tion from the ERE. The activation oftran-
scription by these agents was completely
antagonized by the pure antiestrogen ICI
164,384 (1 x 10-7 M). These data are
shown in Figure 1. EGF in this figure refers
to the mouse receptor-grade EGF used in
the original pellet studies. It is clear from
these data that the ER is required for the
peptide growth factors to elicit transcrip-
tion from the ERE. In addition, the effects
ofEGF and TGFa were inhibited approxi-
mately 70% by a mixture of human EGF
receptor-neutralizing antibodies (Upstate
BiotechnologyInc., Waltham, MA) (26,27),
which demonstrated that the growth factors
are dependent on the extracellular receptor
for activity in this model. Neither basal
transcription nor the effect ofestradiol was
inhibited by the antibodies. Interestingly,
the combination of170-estradiol (1 x10-10)
with either EGF or TGFa elicited ERE-
dependent transcription of larger magni-
tude than the sum oftheir separate effects.
Z
40 - No prox
i>35 - I CI16420A
-I; "10 a.0
0 Control E6F REGF RTGF Esrdial
Figure 1. Effectof ICI 164,384 on CATactivity induced by
EGF,TGFa, orestradiol in Ishikawa cellstransfectedwith
vit A2 ERE and mouse ER. Cell culture and transfection
were performed as described in the text. Transfected
cells were pretreated for 30 min with 1x10-7 M ICI
164,384 before addition of 100 ng/ml mouse receptor
grade EGF, human recombinant EGF (REGF), human
recombinant TGFa (RTGF), or 1 x10-8M 17,-estradiol.
No pretx refers to the groups that did not receive ICI
164,384 pretreatment. The orderofsamples in the repre-
sentativeautoradiogram isthe same asthatin thegraph.
Data are expressed asthe mean ±SEM and are a pool of
three to sixsamplesfromfourseparate experiments.
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The results in the Ishikawa cells sup-
ported our cross-talk hypothesis derived
from the in vivo experiments. However, we
wished to corroborate the in vitro data in a
cell line that contained endogenous ER as
opposed to receptors replaced by transfec-
tion. This type ofmodel is also optimal for
experiments in which the signal-transduc-
tion pathways that may mediate the
growth factor interaction with the ER can
be elucidated. We discovered that the BG-
1 human ovarian adenocarcinoma cell line
(28) contains abundant ER as assessed by
immunodetection with H222 antibody.
TGFax and IGF-I at 1, 10, or 100 ng/ml
stimulated proliferation of BG-1 cells over
a 3-day period in serum-free medium in a
dose-dependent manner. At the highest
dose, an increase of approximately 200 to
250% was observed. 17p-estradiol
(1 x 10-10 M) only stimulated proliferation
approximately 20%; however, in combina-
tion with IGF-I, a greater than additive
effect was observed, which suggests an
interaction between IGF-I and estrogen.
Since the BG-1 cells responded to both
TGFa and IGF-I, we then performed
experiments to determine ifthe growth fac-
tors could regulate endogenous ER with
respect to enhanced transcriptional activa-
tion. We performed transfection experi-
ments as described above except that the
mouse ER expression vector was not
included and the cells were starved in 0.5%
fetal bovine serum/DMEM-F12 media for
24 hr before transfection. EGF, TGFa,
and IGF-I (100 ng/ml) induced CAT
activity in BG-1 cells transfected with the
vitA2 ERE-CAT vector. IGF-I had activ-
ity similar to estradiol (1 x 10-10 M) elicit-
ing a 10- to 12-fold induction, whereas
EGF and TGFa elevated CAT levels
approximately 4-fold.
One potential explanation for this
effect is an elevation of ER levels induced
by growth factor treatment. However,
under conditions described for the trans-
fection assays, TGFa induced a gradual
decrease in receptor to approximately 50%
control at 18 hr posttreatment as assessed
by immunodetection and quantitation of
[125I]-secondary antibody bound to the
blot with an image analysis system from
Molecular Dynamics (Sunnyvale, CA). As
expected, estradiol treatment produced the
same effect on ER levels. Increased prote-
olytic degradation ofthe mouse uterine ER
after estradiol treatment has been previ-
ously reported (29). Thus, the effect ofthe
peptide growth factors was not dependent
on enhanced ER levels. To rule out the
possibility that the strong sv4O promoter
could be responsible for the growth factor
activity, we performed transfection experi-
ments using a reporter vector that con-
tained a minimal promoter, namely the
adenovirus Elb TATA box (30) upstream
of a vitellogenenin A2 promoter fragment
containing a consensus ERE (a gift from
John Cidlowski, University of North
Carolina). Both TGFa and IGF-I acti-
vated transcription using this reporter vec-
tor. Transcriptional activation induced by
TGFa, IGF-I, and 17,B-estradiol with
either the sv4O or Elb minimal promoter
was completely inhibited with ICI 164,384
( X 10-7 M). Thus transcriptional activa-
tion in the BG-1 model is also dependent
on the presence ofthe estrogen receptor.
Similar to the results obtained in the
Ishikawa cells, both TGFa and IGF-I in
combination with estradiol induced CAT-
activity levels that were greater than the
sum oftheir separate activity. However, an
interaction between IGF-I and TGFa
treatments was not observed. One explana-
tion for the observed synergism is that the
growth factor-signaling mechanism induces
ER conformational changes that are differ-
ent from and are cooperative with those
induced by ligand binding. Synergism
between peptide growth factors and
steroids has been reported previously.
IGF-I and estrogen synergistically induced
progesterone receptor levels in MCF-7
breast cancer cells (17). Synergism
between progesterone and EGF in T47D
mammary tumor cells transfected with a
progesterone response element has also
been reported (31). In addition, the inter-
action between dopamine and the ER in
HeLa cells is very similar to that of EGF
and ER (32). Dopamine alone stimulated
transcription in cells transfected with an
ERE and an estrogen receptor expression
vector in an ER-dependent manner. The
combination of submaximal amounts of
dopamine and 17,-estradiol induced CAT
activity more than either agonist by itself.
The next set of experiments began to
address the elucidation of signaling path-
ways involved in the interaction between
peptide growth factors and the estrogen
receptor. In BG-1 cells transfected with the
vitA2-sv40-ERE reporter construct, treat-
ment with the protein kinase C activator
phorbol 12-myristate 13-acetate (TPA,
100 nM) resulted in a 40-fold increase in
transcription whereas 17 -estradiol
(1 x 10-10 M) elicited only 50% of that
level ofactivity. However, the combination
of estradiol and TPA induced a 180-fold
increase in CAT activity. Synergism was
not observed in combination treatments
with TPA and either IGF-I or TGFa. ICI
164,384 inhibited the effect of TPA,
demonstrating a dependence on the ER for
the enhancement of CAT acitivity.
Bisindolylmaleimide (1 jiM), an antagonist
of PKC, completely inhibited the effect of
TPA but had no effect on 17,B-estradiol or
the peptide growth factor effects. Thus, the
protein kinase C pathway does not mediate
the effects of 170-estradiol or peptide
growth factors on the ER in BG-1 cells.
The TPA experiments were repeated using
the Elb minimal promoter construct with
very similar results. Finally, an activator of
protein kinase A, 8 bromoadenosine 3'5'
cyclic monophosphate (8 Br cAMP,
1 x104 M) elicited only a 3.5-fold increase
in CAT activity while TGFa, IGF-I, and
170-estradiol induced 7.5-, 14.5-, and
11-fold increases in CAT activity. Additivity
was observed in combinations of peptide
growth factors or 170-estradiol with 8 Br
cAMP; the effect of8 Br cAMP was blocked
by ICI 164,384. Given the weak activation
observed at a high dose of 8 Br cAMP, it
seems unlikely that the protein kinase A
pathway mediates the effects ofthe peptide
growth factors or 17p-estradiol.
Aronica and Katzenellenbogen (33)
have recently shown that 170-estradiol,
IGF-I, and protein kinase A activators simi-
larly enhance transcription (8- to 10-fold)
from a minimal promoter-the ERE
reporter construct transfected into ER-posi-
tive rat primary uterine cells. Transcrip-
tional activation by these agonists was
inhibited by ICI 164,384 or H8, a protein
kinase A inhibitor. They concluded from
these results that, in their system, the effects
of IGF-I and 17j-estradiol are mediated
through the activity ofPKA. Similar to our
findings in BG-1 cells, they did not observe
synergism with the PKA agonist. Aronica
and Katzenellenbogen (34) also reported
that in ER-positive MCF-7 cells and ER-
negative CHO cells theyobservedveryweak
transcriptional activation when these cells
were treated with either a protein kinase A
or C activator. In MCF-7 cells, the combi-
nation of170-estradiol with a protein kinase
A or C activator elicited synergistic activa-
tion of transcription. However, only the
protein kinase A interaction with 17p-estra-
diol is synergistic in CHO cells. The results
of the Katzenellenbogen laboratory taken
together with our observations point to cell-
specific second-messenger regulation of the
effects of extracellular ligands on nuclear
hormone receptor transcriptional activation.
The presence of cross talk between
peptide-growth factor receptors and the
estrogen receptor suggests that interactions
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between growth factors and steroid recep-
tors may modulate hormonal activity
influencing normal and aberrant function
in mammalian cells. The problems inher-
ent in inappropriate exposure to estrogens
through environmental sources may extend
to chemicals that could activate peptide-
growth factor signaling systems. Thus,
environmental agents that do not appear to
be estrogens from their chemical structures
may act as estrogens through intracellular
signaling to the nuclear estrogen receptor.
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